US Patent 11407813 Anti-VEGF protein compositions and methods for producing the same

Is a

Patent

Patent attributes

Patent Applicant

Regeneron Pharmaceuticals

Current Assignee

Regeneron Pharmaceuticals

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

11407813

Patent Inventor Names

Andrew Tustian0

Thomas Daly0

Shunhai Wang0

Nisha Palackal0

Ning Li0

Matthew Franklin0

Erica Pyles0

Ankit Vartak0

Date of Patent

August 9, 2022

Patent Application Number

17492440

Date Filed

October 1, 2021

Patent Citations

‌

US Patent 10464992 VEGF antagonist formulations suitable for intravitreal administration

‌

US Patent 10144944 Methods of cell culture

‌

US Patent 10400025 VEGF antagonist formulations suitable for intravitreal administration

‌

US Patent 10392430 Methods of making nucleic acid molecules encoding modified chimeric polypeptides with improved pharmacokinetic properties

‌

US Patent 10406226 Method of manufacturing VEGF antagonist fusion proteins

‌

US Patent 10772972 Anti-STEAP2 antibody drug conjugates, and compositions and uses thereof

‌

US Patent 10738130 Bispecific antigen-binding molecules that bind MUC16 and CD3, and compositions thereof

‌

US Patent 10646456 Methods of administering amantadine

...

Patent Citations Received

‌

US Patent 12103960 VEGF traps and mini-traps and methods for treating ocular disorders and cancer

‌

US Patent 11753459 Anti-VEGF protein compositions and methods for producing the same

Patent Primary Examiner

CPC Code

The present disclosure pertains compositions comprising anti-VEGF proteins and methods for producing such compositions.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

US Patent 11407813 Anti-VEGF protein compositions and methods for producing the same

Contents

Patent attributes

Timeline

Further Resources

References

Find more entities like US Patent 11407813 Anti-VEGF protein compositions and methods for producing the same